Timothy P Clackson Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Timothy Clackson FMTX stock SEC Form 4 insiders trading

Timothy has made over 1 trades of the Forma Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Timothy sold 35,067 units of FMTX stock worth $701,691 on 23 June 2020.

The largest trade Timothy's ever made was selling 35,067 units of Forma Therapeutics stock on 23 June 2020 worth over $701,691. On average, Timothy trades about 1,948 units every 0 days since 2018.

You can see the complete history of Timothy Clackson stock trades at the bottom of the page.

What's Timothy Clackson's mailing address?

Timothy's mailing address filed with the SEC is C/O FORMA THERAPEUTICS HOLDINGS, INC., 300 NORTH BEACON STREET, SUITE 501, WATERTOWN, MA, 02472.

Insiders trading at Forma Therapeutics

Over the last 4 years, insiders at Forma Therapeutics have traded over $446,330 worth of Forma Therapeutics stock and bought 9,000,000 units worth $180,000,000 . The most active insiders traders include Capital Management, L.P.Ra ..., Peter Kolchinsky, and Capital Management, L.P.Ra .... On average, Forma Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of $10,575,905. The most recent stock trade was executed by Patrick F. Kelly on 13 April 2022, trading 15,000 units of FMTX stock currently worth $75,750.

What does Forma Therapeutics do?

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.

Complete history of Timothy Clackson stock trades at Spring Bank Pharmaceuticals and Forma Therapeutics

Forma Therapeutics executives and stock owners

Forma Therapeutics executives and other stock owners filed with the SEC include:

• Frank D. Lee,
  Pres, CEO & Director
• Dr. Patrick F. Kelly M.D.,
  Sr. VP & Chief Medical Officer
• Todd E. Shegog,
  Sr. VP & CFO
• Dr. Ifeyinwa Osunkwo M.D., M.P.H.,
  Sr. VP & Chief Patient Officer
• Andrew Littlehale MBA,
  Treasurer
• Brian Lesser,
  Sr. VP of Commercial
• Mary E. Wadlinger,
  Sr. VP of Corp. Affairs & Chief HR Officer
• Scott N. Boyle Ph.D.,
  VP of Bus. and Corp. Devel.
• Dr. Jeannette Potts J.D., Ph.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. David N. Cook Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. John E. Bishop Ph.D.,
  Sr. VP & Chief Technology Officer
• Arturo Md Molina,
  Director
• Wayne A.I. Frederick,
  Director
• Steven Edward Hall,
  Director
• Todd Shegog,
  SVP, Chief Financial Officer
• Timothy P Clackson,
  Director
• Peter Wirth,
  Director
• Peter Kolchinsky,
  Director
• Paolo Paoletti,
  Director
• Mary E. Wadlinger,
  See Remarks
• Marsha Fanucci,
  Director
• Frank D. Lee,
  President and CEO
• Jeannette Potts,
  See Remarks
• David N Cook,
  SVP, Chief Scientific Officer
• Thomas G Wiggans,
  Director
• Capital Management, L.P.Ra ...,
  
• Biomedical Innovation Maste...,
  10% owner
• Selwyn M Md Vickers,
  Director
• Capital Management, L.P.Ra ...,
  
• John E Bishop,
  SVP, Chief Technology Officer
• Patrick F. Kelly,
  SVP, Chief Medical Officer
• Agustin Melian,
  EVP, Research & Development